pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,123
stories
2h
Opinion: Why the FDA should not approve an ineffective multicancer screening test
stat
18h
FDA delays Novo’s hemophilia A drug review over factory issues
endpoints
19h
Shionogi pays $2B to acquire a rare disease startup
biopharma dive
21h
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy
stat
21h
Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
biopharma dive
21h
STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
stat
23h
Could we one day vaccinate against every cancer?
stat
1d
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
fiercebiotech
1d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
1d
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
1d
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
1d
Opinion: FDA must ensure American patients can access new and experimental drugs
biospace
1d
FDA signs off on first heart valve designed to dynamically expand in children
fiercebiotech
1d
Trump announces $90 payments for seniors’ Medicare premium costs ahead of midterm elections
stat
3d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
3d
Foghorn cuts 40% of workforce
biospace
3d
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
4d
FDA Approves First Heart Valve Designed to Grow with Children
fda press
4d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
4d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
4d
United Therapeutics' legal victory; BMS' Camzyos approved for kids
endpoints
5d
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
biospace
5d
STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
stat
5d
Opinion: I studied GLP-1 use in children. The results are reassuring
stat
5d
Euro Roundup: Council of the EU adopts ‘pharma package’ to advance legislative reform agenda
raps
5d
New biotech alliance tells Congress to fight for US dominance
endpoints
5d
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
5d
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
biospace
5d
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
biopharma dive
5d
STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader
stat
← prev
page 1 of 38
next →
